The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study.
 
Marc Oliva Bernal
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Mirati Therapeutics
Travel, Accommodations, Expenses - MSD Oncology
Other Relationship - Merck
 
Daniel Vilarim Araujo
Honoraria - BMS Brazil; GlaxoSmithKline; Libbs
 
Douglas Brian Chepeha
No Relationships to Disclose
 
Amy Prawira
Research Funding - Akeso Biopharma (Inst); Arcus Biosciences (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); CStone Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Henlius (Inst); Hutchison MediPharma (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); QBiotics (Inst); Roche/Genentech (Inst); Virogin Biotech (Inst)
 
Anna Spreafico
Honoraria - Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
Scott Victor Bratman
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Nektar
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.
Travel, Accommodations, Expenses - AstraZeneca
 
Tina Shek
No Relationships to Disclose
 
John R de Almeida
No Relationships to Disclose
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Andrew J. Hope
Travel, Accommodations, Expenses - Elekta
 
David Paul Goldstein
Stock and Other Ownership Interests - IVIV Health (I); Merck (I)
 
Ilan Weinreb
No Relationships to Disclose
 
Bayardo Perez-Ordonez
No Relationships to Disclose
 
Trevor John Pugh
Honoraria - Chrysalis Biomedical Advisors; Merck; Prosigna
Consulting or Advisory Role - DynaCare
Research Funding - Boehringer Ingelheim (Inst)
Patents, Royalties, Other Intellectual Property - Combined hybrid-capture DNA sequencing for disease detection; Hybrid-capture sequencing for dete rmining immune cell clonality
 
Pamela S Ohashi
Consulting or Advisory Role - Providence Therapeutics; Tessa Therapeutics
 
Ben X Wang
No Relationships to Disclose
 
Jonathan Crawford Irish
No Relationships to Disclose
 
Hirak Der-Torossian
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Isan Chen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; GlaxoSmithKline; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)